Form D · Biotechnology
Efferent Labs, Inc.
Buffalo, NY · CIK 0001662565
Offering snapshot reported Apr 16, 2020 · SEC filing
- Reported sold
- Yet to sell Offering amount: $3M
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 16, 2020 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Jan 10, 2018 | Amendment | $960,000 | $530,000vs May 11, 2017 | 12 | SEC filing |
| May 11, 2017 | Amendment | $430,000 | No comparison | 9 | SEC filing |
| Jan 4, 2016 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-365190
Convertible Promissory Note
Source: Form D, filed Apr 16, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Bradford Berk | Director |
| Matthew Colpoys | Executive |
| John Greco | Executive |
| Brian Mc Ilroy | Executive |
| Dante Pennacchia | Director |
| Kristian Pettengill | Executive |
| William Kyle Rader | Director, Executive |
| Efrain Rivera | Director |
| Spencer Rosero | Director, Executive |
| Carl Yankowski | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
700 Ellicott Street
Buffalo, NY, 14203
Buffalo, NY, 14203